Merck Serono S. A.

Laboratoires Serono S.a.

Laboratories Serono Sa

Pierre-Alain Vitte

Agnes Bombrun

Catherine Jorand-Lebrun

Michel Dreano

Jean-Pierre Gotteland

Thomas Rueckle

Pascale Gaillard

Patrick Gerber

Norman Cameron

Mary Anne Cotter

The invention relates to the use a substance signaling through gp130 for the manufacture of a medicament for the treatment and/or prevention of diabetic neuropathy. The use of IL-6 is preferred.

Use of gp130 activators in diabetic neuropathy

The present invention relates to the use of IL-6 or a fragment, variant, fusion protein, functional derivative or salt thereof in microvascular complications.

Method for inhibiting a microvascular complication by administering IL-6

The present invention relates to the use of IL-6 in compositions and methods for therapy or prevention of chemotherapy-induced neuropathy (CIPN). More specifically, the invention relates to the use of a low dose of IL-6 for the treatment and/or prevention CIPN.

Compositions and methods for therapy or prevention of chemotherapy-induced neuropathy

The present invention is related to the use of sulfonamide derivatives in the treatment of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type II, inadequate glucose tolerance, insulin resistance, obesity, polycystic ovary syndrome (PCOS). Formula (I). Ris selected from the group comprising or consisting of hydrogen, C-C-alkoxy, C-C-alkyl, C-C-alkenyl, C-C-alkynyl, amino, sulfanyl, sulfinyl, sulfonyl, sulfonyloxy, sulfonamide, acylamino, aminocarbonyl, C-Calkoxycarbonyl, aryl, heteroaryl, carboxy, cyano, halogen, hydroxy, nitro, hydrazides. Ris selected from the group comprising or consisting of hydrogen, COOR3, &#x2014;CONRR, OH, a C-Calkyl substituted with an OH or amino group, a hydrazido carbonyl group, a sulfate, a sulfonate, an amine or an ammonium salt. Y is an 4-12-membered saturated cyclic or bicyclic alkyl containing at least one nitrogen atom, whereby one nitrogen atom within said ring is forming a bond with the sulfonyl group of formula I thus providing the sulfonamide. 

Sulfonamide derivatives for the treatment of diabetes

The present invention is related to piperazine henzothiazole derivatives, notably for use in the treatment and/or prophylaxis of cerebral ischemic disorders or CNS disorders. The present invention is furthermore related to methods of their preparation.

Growing community of inventors

Cranves-Sales, France

Pierre-Alain Vitte